Monthly report from the EU Pharmacovigilance Risk Assessment Committee (PRAC) - September 2014

17 September 2014, Updated 23 September 2014

The EU Pharmacovigilance Risk Assessment Committee (PRAC) convened on 8-11 September 2014. Topics discussed at the meeting:

  • PRAC concludes review of Valdoxan/Thymanax (agomelatine).
  • Two years of focus on patient safety.
  • One month left to respond to the consultation on public hearings.

Read PRAC's monthly report from the meeting 8-11 September 2014

Did you get answers to your questions?

Please tell us how we can improve our website? Please note that we do not answer questions asked via this feature.


...